NCT03387332View on ClinicalTrials.gov

APG-1252 in Patients With SCLC or Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

November 9, 2020

Study Completion Date

April 15, 2021

Conditions
Small Cell Lung Cancer and Other Solid Tumors
Interventions
DRUG

APG-1252

Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.

Trial Locations (1)

510080

Guangdong General Hospital, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Suzhou Yasheng Pharmaceutical Co., Ltd.

INDUSTRY

lead

Ascentage Pharma Group Inc.

INDUSTRY